CHRS Q4 2019 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$124M

Gross Profit

$116M93.7% margin

Operating Income

$45M36.4% margin

Net Income

$39M31.7% margin

EPS (Diluted)

$0.53

QoQ Revenue Growth

+10.9%

Cash Flow

Operating Cash Flow

$18M

Free Cash Flow

$17M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$409M

Total Liabilities

$304M

Stockholders' Equity

$105M

Cash & Equivalents

$178M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$124M	$0	—
Gross Profit	$116M	-$27M	+535.3%
Operating Income	$45M	-$61M	+174.4%
Net Income	$39M	-$63M	+162.7%